Questionnaire Survey Regarding the Current Status of Super-extended Lymph Node Dissection in Japan

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2016 Sep 28

PMID 27672429

Citations 3

Authors

Shinji Morita

Takeo Fukagawa

Hisataka Fujiwara

Hitoshi Katai

Affiliations

Soon will be listed here.

Abstract

Aim: To verify the current status of super-extended lymph node dissection for advanced gastric cancer according to a questionnaire survey.

Methods: One-hundred and five institutions responded to the questionnaire. The survey included the following items: Number of experiences, whether performed prophylactically and/or therapeutically, whether preoperative chemotherapy was provided, number of preoperative chemotherapy rounds, and therapeutic options after chemotherapy.

Results: Eighty-seven of the 105 institutions (83%) had performed D3 gastrectomy in the past or continued to perform D3 gastrectomy at present. However, D3 gastrectomy was rarely performed prophylactically in clinical practice. Seventy-eight institutions (74%) indicated that preoperative chemotherapy with curative intent was required for patients suspected of having para-aortic node (PAN) metastases. After chemotherapy, a D3 gastrectomy was scheduled for patients with a complete or partial response, stable disease, and progressive disease at 36 (46%), 28 (36%), and 13 (17%) of the institutions, respectively.

Conclusion: For patients with apparent PAN metastasis, a D3 gastrectomy is typically planned if a few courses of preoperative chemotherapy yield at least a stable disease condition.

Citing Articles

Advances in para-aortic nodal dissection in gastric cancer surgery: A review of research progress over the last decade.

Dong Y, Deng J World J Clin Cases. 2020; 8(13):2703-2716.

PMID: 32742981 PMC: 7360716. DOI: 10.12998/wjcc.v8.i13.2703.

Prognostic significance of 14v-lymph node dissection to D2 dissection for lower-third gastric cancer.

Zheng C, Gao Z, Sun A, Huang H, Wang Z, Li K World J Clin Cases. 2019; 7(18):2712-2721.

PMID: 31616687 PMC: 6789393. DOI: 10.12998/wjcc.v7.i18.2712.

Recent trends from the results of clinical trials on gastric cancer surgery.

Kiyokawa T, Fukagawa T Cancer Commun (Lond). 2019; 39(1):11.

PMID: 30917873 PMC: 6437915. DOI: 10.1186/s40880-019-0360-1.

References

Ajani J, Ota D, Jessup J, Ames F, McBride C, Boddie A . Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991; 68(7):1501-6. DOI: 10.1002/1097-0142(19911001)68:7<1501::aid-cncr2820680706>3.0.co;2-l. View

Leichman L, SILBERMAN H, Leichman C, Spears C, Ray M, Muggia F . Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol. 1992; 10(12):1933-42. DOI: 10.1200/JCO.1992.10.12.1933. View

Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M . Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014; 101(6):653-60. DOI: 10.1002/bjs.9484. View

Lee W, Lee P, Yue S, Chang K, Wei T, Chen K . Lymph node metastases in gastric cancer: significance of positive number. Oncology. 1995; 52(1):45-50. DOI: 10.1159/000227426. View

Hartgrink H, van de Velde C, Putter H, Songun I, Tesselaar M, Kranenbarg E . Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004; 30(6):643-9. DOI: 10.1016/j.ejso.2004.04.013. View

Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K . Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009; 96(9):1015-22. DOI: 10.1002/bjs.6665. View

Ott K, Sendler A, Becker K, Dittler H, Helmberger H, Busch R . Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003; 6(3):159-67. DOI: 10.1007/s10120-003-0245-4. View

Maruyama K, Okabayashi K, Kinoshita T . Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987; 11(4):418-25. DOI: 10.1007/BF01655804. View

Yonemura Y, Katayama K, Kamata T, Fushida S, Segawa M, Ooyama S . Surgical treatment of advanced gastric cancer with metastasis in para-aortic lymph node. Int Surg. 1991; 76(4):222-5. View

10.

Sasako M, McCulloch P, Kinoshita T, Maruyama K . New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995; 82(3):346-51. DOI: 10.1002/bjs.1800820321. View

11.

Baba M, Hokita S, Natsugoe S, Miyazono T, Shimada M, Nakano S . Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper-third of the stomach. Hepatogastroenterology. 2000; 47(33):893-6. View

12.

Marrelli D, Mazzei M, Pedrazzani C, Di Martino M, Vindigni C, Corso G . High accuracy of multislices computed tomography (MSCT) for para-aortic lymph node metastases from gastric cancer: a prospective single-center study. Ann Surg Oncol. 2011; 18(8):2265-72. DOI: 10.1245/s10434-010-1541-y. View

13.

Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I . Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011; 14(4):301-16. PMC: 3196643. DOI: 10.1007/s10120-011-0085-6. View

14.

Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J . Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol. 1996; 14(6):1818-28. DOI: 10.1200/JCO.1996.14.6.1818. View

15.

Ajani J, Mansfield P, Janjan N, Morris J, Pisters P, Lynch P . Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004; 22(14):2774-80. DOI: 10.1200/JCO.2004.01.015. View

16.

Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A . D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008; 359(5):453-62. DOI: 10.1056/NEJMoa0707035. View

17.

Ajani J, Mayer R, Ota D, Steele G, Evans D, Roh M . Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993; 85(22):1839-44. DOI: 10.1093/jnci/85.22.1839. View

18.

Mezhir J, Tang L, Coit D . Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol. 2010; 101(4):305-14. DOI: 10.1002/jso.21483. View

19.

Leake P, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A . A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer. 2011; 15 Suppl 1:S38-47. DOI: 10.1007/s10120-011-0047-z. View

20.

Persiani R, Rausei S, Pozzo C, Biondi A, Barone C, Cananzi F . 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol. 2008; 15(8):2146-52. DOI: 10.1245/s10434-008-9982-2. View